AIM ImmunoTech Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
AIM$0.14-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025, and 2024
December 31, 2025 and 2024
(in thousands, except for share and per share amounts)
| 2025 | 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $2,985 | $1,701 |
| Marketable securities | 62 | 2,276 |
| Other receivable | 7 | — |
| Prepaid expenses and other current assets | 241 | 199 |
| Total current assets | 3,295 | 4,176 |
| Property and equipment, net | 71 | 108 |
| Right of use asset, net | 378 | 618 |
| Patent and trademark rights, net | 1,661 | 2,594 |
| Other assets | 377 | 1,112 |
| Total assets | $5,782 | $8,608 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $1,630 | $6,383 |
| Accrued expenses | 795 | 606 |
| Current operating lease liability | 250 | 239 |
| Current note payable, net | 3,549 | 2,307 |
| Total current liabilities | 6,224 | 9,535 |
| Long-term liability: | ||
| Operating lease liability | 170 | 395 |
| Long-term note payable | 927 | — |
| Warrant liability | 8,244 | — |
| Total liabilities | 15,565 | 9,930 |
| Commitments and contingencies (Notes 7, 8, 10) | - | - |
| Stockholders’ deficit: | ||
| Series A Junior Participating Preferred Stock, $0.01 par value, 4,000,000 shares authorized as of December 31, 2025 and 2024; issued and outstanding – none | — | — |
| Series B Convertible Preferred Stock, stated value $1,000 per share, 10,000 shares authorized; as of December 31, 2025 and 2024; issued and outstanding - none | — | — |
| Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 3,069,875 and 655,262 as of December 31, 2025 and 2024, respectively | 3 | 1 |
| Additional paid-in capital | 431,000 | 425,505 |
| Accumulated deficit | (440,786) | (426,828) |
| Total stockholders’ deficit | (9,783) | (1,322) |
| Total liabilities and stockholders’ deficit | $5,782 | $8,608 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.